Learn how GLP-1 medications support weight loss and heart health in perimenopause and postmenopause, plus get tips for ...
Learn the key differences between obstructive and nonobstructive HCM, including how your specific diagnosis can impact ...
Investor's Business Daily on MSN
BioAge rockets as it takes on Eli Lilly's takeover play, Ventyx Bio
BioAge shares catapulted Monday on promising results for the company's cardiovascular diseases treatment, which could ...
While frustrating for physicians, the emerging evidence should spur “hypervigilance” around risks that are socially determined.
Social determinants of health influence heart failure and arrhythmia risk in HCM, highlighting the need for more holistic, ...
The annual report covers the five most impactful cardiovascular diseases, aiming for accountability and action.
Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...
FDA-cleared AI-CVD® extracts preventive insights from routine CT—identifying hidden cardiovascular, metabolic, and ...
The American College of Cardiology issued its inaugural JACC Cardiovascular Statistics report, highlighting the prevalence of ...
Brigham and Women's Hospital investigators link very high lipoprotein(a) with a higher 30-year risk of major cardiovascular ...
The new U.S. dietary guidelines prioritize certain sources of saturated fats. The change concerns experts in nutrition.
The American College of Cardiology found uneven gains and sobering declines in heart health. "You can't treat your way out of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback